CRTAP Antibody

Code CSB-PA005999GA01HU
Size $600
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
CRTAP
Alternative Names
CRTAP antibody; CASPCartilage-associated protein antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse,Rat
Immunogen
Human CRTAP
Immunogen Species
Homo sapiens (Human)
Isotype
IgG
Purification Method
Antigen Affinity purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
PBS with 0.1% Sodium Azide, 50% Glycerol, pH 7.3. -20°C, Avoid freeze / thaw cycles.
Tested Applications
ELISA,WB,IHC
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Necessary for efficient 3-hydroxylation of fibrillar collagen prolyl residues.
Gene References into Functions
  1. To the best of our knowledge, our study is the first to exclude potential correlations between heterozygous variants in CRTAP and milder skeletal impairments in a large number of patients PMID: 27901313
  2. This study enhances our knowledge about the mutational pattern of the LEPRE1, CRTAP, and PPIB genes. LEPRE1 should be the first gene analyzed in mutation detection studies in patients with recessive OI. PMID: 26634552
  3. An additional function of the rough endoplasmic reticulum protein complex prolyl 3-hydroxylase 1.cartilage-associated protein.cyclophilin B: the CXXXC motif reveals disulfide isomerase activity in vitro. PMID: 24043621
  4. SNP rs7623768 and the haplotype G-C of rs4076086-rs7623768 in CRTAP were associated with femoral neck bone mineral density (p = 0.009 and p = 0.003, respectively). PMID: 19727905
  5. Importantly, human mutations in the CRTAP gene have been associated with recessive forms of OI. PMID: 20425614
  6. CRTAP deficiency results in higher bone mineral content of the bone matrix in osteogenesis imperfecta type VII. PMID: 19895918
  7. Null mutations in LEPRE1 and CRTAP cause severe recessive osteogenesis imperfecta. PMID: 19862557
  8. CRTAP and P3H1 are mutually stabilized in the collagen prolyl 3-hydroxylation complex in endoplasmic reticulum. PMID: 19846465
  9. CRTAP mutations not described earlier were identified in 10 individuals who had a clinical diagnosis of lethal and severe osteogenesis imperfecta. PMID: 19550437
  10. complexes with prolyl 3-hydroxylase 1 (P3H1) to decrease prolyl 3 hydroxylation; dysregulation of prolyl 3 hydroxylation is a mechanism for connective tissue disease PMID: 17055431
  11. Screening of 78 subjects diagnosed with osteogenesis imperfecta type II or III, identified three probands with mutations in CRTAP and 16 with mutations in LEPRE1. PMID: 18566967
  12. Mutations in CRTAP and LEPRE1 are found in 3 patients with type II osteogenesis imperfecta. PMID: 18996919

Show More

Hide All

Involvement in disease
Osteogenesis imperfecta 7 (OI7)
Subcellular Location
Secreted, extracellular space, extracellular matrix.
Protein Families
Leprecan family
Tissue Specificity
Found in articular chondrocytes. Expressed in a variety of tissues.
Database Links

HGNC: 2379

OMIM: 605497

KEGG: hsa:10491

STRING: 9606.ENSP00000323696

UniGene: Hs.517888

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*